CRM.WAR PZ Cormay SA
- Market cap
- PLN 41.2M
- P/E
- -
- P/B
- 0.95x
- ROE
- -10.8%
- Dividend yield
- -
- Fundamental score
- 1.4/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is CRM.WAR undervalued?
Graham numberThe Graham number of PZ Cormay SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PZ Cormay SA fundamental analysis
7 of 21 checks passedROE 0/2
Low return on equity (-10.8%), below 10%.
ROA 0/1
Return on assets (-4.9%) is below the industry median (2.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (21.0%) is above the industry median (5.1%).
Revenue Growth 1/2
Revenue grew 4.1% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (37.6%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.8 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (1.0x) is below the industry median (1.5x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
PZ Cormay SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PZ Cormay SA
PZ Cormay S.A., a diagnostic company, provides IVD solutions in Poland and internationally. The company offers analyzers, reagents, cleaning liquids, calibrators, control materials, patterns, and agglutination tests. It also provides analyzers, test strips, inspections, and calibration strips. In addition, the company offers parasitology, such as Paragreen Mini-System, a specialized device for concentrating and preserving stool samples, as well as veterinary medicines. Furth…
Full company profilePZ Cormay SA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PZ Cormay SA annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 82.3M | 77.6M | 69.8M | 68.4M | 65.3M | 84.7M | 85.4M | 82.2M | 91.6M | 96.3M | 100M |
| Gross Profit | 31.3M | 31.1M | 28.1M | 26.9M | 26.5M | 34.5M | 34.9M | 33.6M | 33.6M | 37.9M | 40.8M |
| Operating Income | -7.79M | -8.72M | -27.3M | -42.8M | -7.30M | -68.0K | -4.31M | -5.30M | -4.96M | -3.48M | 16.0K |
| EBITDA | -11.2M | 445K | -23.0M | -36.5M | -8.05M | 6.52M | -992K | 2.23M | 1.07M | 2.52M | 6.01M |
| Net Income | -11.0M | -2.02M | -25.0M | -41.0M | -12.7M | 1.64M | -6.96M | -4.53M | -5.27M | -4.16M | -4.76M |
| EPS | -0.17 | -0.03 | -0.32 | -0.49 | -0.15 | 0.02 | -0.08 | -0.05 | -0.06 | -0.05 | -0.06 |
| Balance Sheet | |||||||||||
| Total Assets | 188M | 175M | 161M | 102M | 93.7M | 99.7M | 102M | 93.9M | 89.7M | 88.2M | 97.3M |
| Total Liabilities | 43.4M | 38.9M | 42.8M | 28.7M | 30.4M | 34.0M | 40.2M | 38.2M | 39.7M | 41.2M | 52.7M |
| Shareholders' Equity | 102M | 129M | 112M | 72.2M | 62.4M | 64.9M | 61.3M | 55.3M | 49.6M | 45.9M | 44.1M |
| Cash & Short-term Investments | 3.33M | 2.15M | 2.35M | 38.4M | 35.9M | 30.6M | 14.9M | 10.0M | 4.65M | 4.65M | 6.28M |
| Total Debt | 621K | 3.03M | 3.38M | 2.13M | 4.65M | 4.09M | 4.07M | 4.91M | 5.96M | 10.2M | 16.6M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -5.17M | 1.66M | -1.56M | -4.39M | -161K | -1.47M | -8.71M | -3.25M | -2.63M | -699K | -6.92M |
| Capital Expenditure | 5.03M | 8.13M | 6.90M | 11.2M | 4.66M | 6.75M | 8.44M | 3.66M | 703K | 1.45M | 1.32M |
| Free Cash Flow | -10.2M | -6.47M | -8.46M | -15.5M | -4.82M | -8.22M | -17.1M | -3.48M | -3.96M | -2.15M | -8.24M |
| Ratios | |||||||||||
| ROE | -10.8% | -1.6% | -22.4% | -56.8% | -20.3% | 2.5% | -11.4% | -8.2% | -10.6% | -9.1% | -10.8% |
| ROA | -5.8% | -1.2% | -15.5% | -40.0% | -13.5% | 1.6% | -6.8% | -4.8% | -5.9% | -4.7% | -4.9% |
| Net Profit Margin | -13.4% | -2.6% | -35.8% | -59.9% | -19.4% | 1.9% | -8.2% | -5.5% | -5.7% | -4.3% | -4.7% |
| Debt to Equity | 0.01x | 0.02x | 0.03x | 0.03x | 0.07x | 0.06x | 0.07x | 0.09x | 0.12x | 0.22x | 0.38x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
PZ Cormay SA dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | PLN 203K | 0.00 | - |
| 2023 | - | - | - |
| 2022 | PLN 5.00K | 0.00 | - |
| 2021 | PLN 279K | 0.00 | 17.1% |
| 2020 | PLN 178K | 0.00 | - |
| 2019 | PLN 178K | 0.00 | - |
| 2018 | PLN 178K | 0.00 | - |
| 2017 | PLN 178K | 0.00 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 29:22 on Jun 11, 2015.
Who owns PZ Cormay SA
- Insiders 0.00%
- Institutions 19.00%
- Public & others 81.00%
- Shares outstanding 84.2M
- Free float 67.9M
PZ Cormay SA company profile
- Company name
- PZ Cormay SA
- Ticker
- CRM.WAR
- ISIN
- PLCMRAY00029
- Exchange
- Warsaw Stock Exchange
- Sector
- Technology
- Industry
- Electronic Equipment, Instruments & Components
- Employees
- 220
- Fiscal year end
- December
- Address
- ul. Wiosenna 22, Lomianki, Poland, 05-092
- Phone
- 48 22 751 7910
- Website
- cormay.com
About PZ Cormay SA
PZ Cormay S.A., a diagnostic company, provides IVD solutions in Poland and internationally. The company offers analyzers, reagents, cleaning liquids, calibrators, control materials, patterns, and agglutination tests. It also provides analyzers, test strips, inspections, and calibration strips. In addition, the company offers parasitology, such as Paragreen Mini-System, a specialized device for concentrating and preserving stool samples, as well as veterinary medicines. Further, it provides immunochemistry, including SNIBE, MINDRAY, and DIESSE, as well as molecular biology, such as RT-PCR systems, systems for isolating genetic material, workstations, RT-PCR reagent kits, and nucleic acid isolation reagent kits. Additionally, the company offers sampling comprising blood and urine samples and supporting materials, as well as Sentimag systems, Magtrace markers, Magseed Markers, and surgical instruments, as well as HPLC systems, point of care diagnostics, and integrated systems. The company was founded in 1985 and is based in Lomianki, Poland.
PZ Cormay SA management
2- Mr. Flavio FinotelloPresident of the Management Board
- Mr. Wojciech SuchowskiVice President of the Management Board